Drug-eluting stents are drug/device combinatory products designed to physically re-establish the blood flow in arteriosclerotic blood vessels and deliver anti-proliferative drugs to the stented vessel section to prevent neointimal hyperplasia. Drug that is released during the implantation procedure is washed away with the blood flow. It was our aim to estimate this drug loss using stents coated with fluorescent model substances in an in vitro setup. Stents mounted on balloon catheters were introduced into a polymethacrylate coronary artery model (adapted from ASTM standard F 2394-07 intended for measurement of securement of stents on delivery systems) via a guiding catheter. The system was perfused by phosphate buffered saline pH 7.4 at a flow-rate adapted to the blood flow-rate in coronary arteries. The perfusate was collected in fractions and model substance content was determined fluorimetrically. The hydrophilic model substance fluorescein sodium was released very fast resulting in a loss of approximately 64 % of the drug load within the first minute and up to 82 % after 5 minutes. The hydrophobic model substance triamterene was released much slower from the coating. A total loss of 5 % was detected after 5 minutes. Furthermore, commercially available sirolimus-eluting Cypher Select ® + stents were tested. Release into the media was not detected. Obviously, the drug-free top coating effectively prevented drug release during the simulated passage to the site of implantation. An in vitro test system to estimate drug loss during the implantation procedure of drug-eluting stents was successfully established. First results using fluorescent model substances indicate that vast losses have to be expected when using fast releasing delivery systems. Therefore, the model may also prove valuable for the in vitro testing of drug-eluting balloons. Further adaptations, such as the inclusion of biorelevant media, may be suitable to further improve the predictability of in vivo performance.
Introduction
Drug-eluting stents (DES) are drug/device combination products designed to prevent the renarrowing of a previously occluded natural passage. The most predominant type of stent is the coronary stent which is intended to restore the blood flow in coronary arteries. It typically consists of a metallic stent body whose struts have been coated with a drug embedded in a polymeric carrier. Additional layers, such as a drug-free topcoat, may be used to control the release behaviour of the incorporated drug substance. The coated stent is mounted and crimped onto a balloon catheter. Using this balloon catheter the DES is transported to the diseased vessel portion and expanded. The combination product is intended to exercise a dual principle of action: the metallic stent backbone is designed to physically prevent the renarrowing of the stented vessel portion and the released drug substance is intended to suppress neointimal hyperplasia which is another potential cause of renarrowing of the treated artery. In spite of the successful implantation of millions of DES up-to date, there is still limited knowledge about the release behaviour of the incorporated drug substance [1] . Furthermore, in the case of DES not only the release of the active substance but also its distribution between the blood and the vessel wall is of greatest importance since drug dissolved in the flowing blood will most likely be cleared from the site of pathology. The vessel-simulating flow-through cell was developed by our group to analyse release and distribution from DES in an in vitro setup [2] . Examination of stents coated with model fluorescent substances using this test system showed, that the in vitro implantation procedure had an impact on the observed distribution of a drug released from a fast releasing stent system [3] . For such systems, the in vitro implantation procedure should carefully be adapted to the situation in vivo. The implantation procedure can be expected to have an even bigger impact in vivo if drug losses occur prior to the expansion of the DES at the target lesion. It was our aim to estimate drug losses occurring during the advancement of the stent system towards the site of expansion in an in vitro model adapted to some of the key factors of the situation in vivo and to the procedural features. During in vivo stent implantation the balloon catheter with the mounted stent is placed over a guidewire which has been placed in the stenosed vessel portion and advanced through a haemostatic valve and a guiding catheter. During the fast passage of the stent system through the guiding catheter the stent is in contact with blood and possibly with saline and contrast agents which are administered via the catheter. Furthermore, contact with the inner wall of the catheter may occur. After leaving the guiding catheter the stent is surrounded by the flowing blood and may come in contact with the vessel wall and plaque. During these processes drug loss due to coating abrasion as well as beginning elution as the drug containing polymer layer comes in contact with liquid is conceivable.
The advancement of the stent through the guiding catheter typically takes less than 30 s. The additional time required for the correct placement of the stent in the stenosis greatly depends on the complex required to position the stent should not exceed 5 min.
Methods

Test method design
In order to emulate the forces acting on a stent coating du ing the passage through the guiding catheter and the vasc lar system, a polymethacrylate model adapted from ASTM standard F 2394 curement of Balloon Expandable Vascular Stent Mounted on Delivery System" veloped for the in vitro physical characterization o livery system including the force required to displace or dislodge a balloon endovascular stent mounted on a delivery system method as well as also been used to characterize catheter-system test system branches. Ho main branch was i lymethacrylate plates: a top and a bo ing the middle plate in which the sim coronary artery is shaped. the polymetha equipped with a guiding catheter ( JL 3.5 LBT, Cordis Europe, Be R3607 inner diameter 3.17 mm, VWR Intern many). The p nected to a haemostatic valve ( adapter and Tuohy Germany). The experimental setup is d Figure 1 Experimental setup with a) model, b) haemostatic valve with c) sealable port for catheter insertion and d) port for medi to pump, e) guiding catheter, f) tube and g) tube outlet and media collection, arrow indicating resting position of stent.
Stents were crimped onto balloon catheters ( Biotronik AG, Switzerland
The advancement of the stent through the guiding catheter typically takes less than 30 s. The additional time required for the correct placement of the stent in the stenosis greatly depends on the complexity of the lesion. Overall, the time required to position the stent should not exceed 5 min.
Methods
Test method design
In order to emulate the forces acting on a stent coating du ing the passage through the guiding catheter and the vasc a polymethacrylate model adapted from ASTM tandard F 2394-07 "Standard Guide for Measuring S curement of Balloon Expandable Vascular Stent Mounted on Delivery System" [4] was built. veloped for the in vitro physical characterization o livery system including the force required to displace or dislodge a balloon endovascular stent mounted on a delivery system method as well as similarly also been used to characterize systems [5, 6] . The sim according to ASTM es. However, in the model pr main branch was included. The model consists of late plates: a top and a bo dle plate in which the sim tery is shaped. metharcylate model built for the experiments was equipped with a guiding catheter ( JL 3.5 LBT, Cordis Europe, Be R3607 inner diameter 3.17 mm, VWR Intern many). The proximal end of the guiding catheter was co nected to a haemostatic valve ( adapter and Tuohy-Borst valve Germany). The experimental setup is d
Experimental setup with a) model, b) haemostatic valve with c) sealable port for ter insertion and d) port for medi to pump, e) guiding catheter, f) tube and g) tube outlet and media collection, arrow indicating resting position of stent. nts were crimped onto balloon catheters ( Biotronik AG, Switzerland
The advancement of the stent through the guiding catheter typically takes less than 30 s. The additional time required for the correct placement of the stent in the stenosis greatly ity of the lesion. Overall, the time required to position the stent should not exceed 5 min.
In order to emulate the forces acting on a stent coating du ing the passage through the guiding Experimental setup with a) polymethacrylate model, b) haemostatic valve with c) sealable port for ter insertion and d) port for media inflow connected to pump, e) guiding catheter, f) tube and g) tube outlet and media collection, arrow indicating resting position of stent. nts were crimped onto balloon catheters (Pantera, ) and inserted via the sealable
In order to emulate the forces acting on a stent coating during the passage through the guiding catheter and the vascua polymethacrylate model adapted from ASTM Standard Guide for Measuring Securement of Balloon Expandable Vascular Stent Mounted This standard was def the dedetermination of the shear expandable endovascular stent mounted on a delivery system. This test systems have the trackability of stentmen in the three side sented here only the three poroundlated course of a specified test system, late model built for the experiments was rite Tip 5F ) and a tube (Tygon tional, Gerroximal end of the guiding catheter was conconnector with rotating , B. Braun Melsungen AG, picted in figure 1. polymethacrylate model, b) haemostatic valve with c) sealable port for inflow connected to pump, e) guiding catheter, f) tube and g) tube outlet and media collection, arrow indicating resting position of stent.
Pantera, ) and inserted via the sealable port of the haemostatic valve thus avoiding media loss du ing stent advancement. The second port was connected to a peristaltic pump. Phosphate buffe to 37 valve, guiding catheter and tube) at a flow rate of 35 mL/min which corresponds to the blood flow velocity in coronary arteries [ vanced through ing position (see arrow figure reach this position was approximately 20 was retained in this position until the perfusion was term nated after 5 ment through the guiding catheter). The media was co lected in fractions by changing the collecting container every 30 the media as well as the amount coating were det quent elution.
Drug
The model was evaluated using stents coated with two model fluorescent substances of differing solubility pro erties. Bare (solubility in water 28 rescein sodium (freely soluble in water [ [11] ) embedded in a polymethacrylate blend (Eudragit RL/RS ratio 3/7). Released model substance content was deter were transferred to a 96 sity was measured using a fluorescence reader Flash, λ ex 370 λ em 515 periment. Samples were protected from light. Furthermore, commercially available and pre Cypher nary stent, length 18 Cordi tested using the same setup. The contained drug substance sirolimus, also known as rapamycin, is poorly soluble in water (2.6 The collected media samples were immediat with methanol (1 + 1 analysis. Quantification of the sirolimus released was pe formed using a HPLC Knauer GmbH ser/gradient module (Manage pump (Smartline 1000), autosampler (Smartline 3800), column oven (Jet Steam Oven) and a UV tline 2600). The used C mm ID, particle size 5 50 °C through performed under isocratic conditions with a mobile phase consisting of acetonitrile/water was set to 1.0 wavelength of 50 µ port of the haemostatic valve thus avoiding media loss du ing stent advancement. The second port was connected to a peristaltic pump. Phosphate buffe to 37 °C was pumped through the system (haemostatic valve, guiding catheter and tube) at a flow rate of mL/min which corresponds to the blood flow velocity in coronary arteries [ vanced through the perfused model until reaching the res ing position (see arrow figure reach this position was approximately 20 was retained in this position until the perfusion was term nated after 5 min (incubation time incl ment through the guiding catheter). The media was co lected in fractions by changing the collecting container every 30 s. The amount the media as well as the amount coating were determined after stent retrieval and subs quent elution.
Drug-eluting
The model was evaluated using stents coated with two model fluorescent substances of differing solubility pro ties. Bare-metal stents were dip (solubility in water 28 rescein sodium (freely soluble in water [ ]) embedded in a polymethacrylate blend (Eudragit RL/RS ratio 3/7). Released model substance content was rmined fluorimetrically. Two were transferred to a 96 sity was measured using a fluorescence reader Flash, Thermo Fisher Scientific Inc., USA; 370 nm, λ em 434 515 nm). Calibration was performed with every e periment. Samples were protected from light. Furthermore, commercially available and pre Cypher stents (Cypher Select nary stent, length 18 Cordis Medizinische Apparate GmbH, Germany) were tested using the same setup. The contained drug substance sirolimus, also known as rapamycin, is poorly soluble in water (2.6 µg/mL [1 The collected media samples were immediat with methanol (1 + 1 analysis. Quantification of the sirolimus released was pe formed using a HPLC Knauer GmbH, Germany) equipped with a dega ser/gradient module (Manage pump (Smartline 1000), autosampler (Smartline 3800), column oven (Jet Steam Oven) and a UV tline 2600). The used C mm ID, particle size 5°C throughout the separation. The chromatography was performed under isocratic conditions with a mobile phase consisting of acetonitrile/water was set to 1.0 mL/min. UV detection was conducted at a wavelength of 278 µL and the retention time amounted to 7.5 port of the haemostatic valve thus avoiding media loss du ing stent advancement. The second port was connected to a peristaltic pump. Phosphate buffe°C was pumped through the system (haemostatic valve, guiding catheter and tube) at a flow rate of mL/min which corresponds to the blood flow velocity in coronary arteries [7] . The mounted stent was rapidly a the perfused model until reaching the res ing position (see arrow figure reach this position was approximately 20 was retained in this position until the perfusion was term min (incubation time incl ment through the guiding catheter). The media was co lected in fractions by changing the collecting container s. The amounts of model substance released into the media as well as the amount ermined after stent retrieval and subs
eluting stent testing
The model was evaluated using stents coated with two model fluorescent substances of differing solubility pro metal stents were dip (solubility in water 28 µg/mL [ rescein sodium (freely soluble in water [ ]) embedded in a polymethacrylate blend (Eudragit RL/RS ratio 3/7). Released model substance content was mined fluorimetrically. Two were transferred to a 96 well plate and fluorescence inte sity was measured using a fluorescence reader Thermo Fisher Scientific Inc., USA; 434 nm; fluorescein sodium nm). Calibration was performed with every e periment. Samples were protected from light. Furthermore, commercially available and pre tents (Cypher Select ® nary stent, length 18 mm, nominal diameter 3.5 s Medizinische Apparate GmbH, Germany) were tested using the same setup. The contained drug substance sirolimus, also known as rapamycin, is poorly soluble in µg/mL [12] ) with a log P value of 5.8 [1 The collected media samples were immediat with methanol (1 + 1 v/v), frozen, and stored at analysis. Quantification of the sirolimus released was pe formed using a HPLC system ( , Germany) equipped with a dega ser/gradient module (Manager 5000), mixing chamber, pump (Smartline 1000), autosampler (Smartline 3800), column oven (Jet Steam Oven) and a UV tline 2600). The used C18 column (Eurospher 100, 120 x 4 mm ID, particle size 5 µm) was kept at a temperature of out the separation. The chromatography was performed under isocratic conditions with a mobile phase consisting of acetonitrile/water mL/min. UV detection was conducted at a 278 nm. The injected sample and the retention time amounted to 7.5 port of the haemostatic valve thus avoiding media loss du ing stent advancement. The second port was connected to a peristaltic pump. Phosphate buffered saline pH 7.4 heated °C was pumped through the system (haemostatic valve, guiding catheter and tube) at a flow rate of mL/min which corresponds to the blood flow velocity ]. The mounted stent was rapidly a the perfused model until reaching the res ing position (see arrow figure 1 ). The time required to reach this position was approximately 20 -30 s. The stent was retained in this position until the perfusion was term min (incubation time including the advanc ment through the guiding catheter). The media was co lected in fractions by changing the collecting container of model substance released into the media as well as the amounts remaining in the stent ermined after stent retrieval and subs
tent testing
The model was evaluated using stents coated with two model fluorescent substances of differing solubility pro metal stents were dip-coated with triamterene µg/mL [8] , log P 1.25 [ rescein sodium (freely soluble in water [10 ] ) embedded in a polymethacrylate blend (Eudragit RL/RS ratio 3/7). Released model substance content was mined fluorimetrically. Two samples of well plate and fluorescence inte sity was measured using a fluorescence reader Thermo Fisher Scientific Inc., USA; nm; fluorescein sodium nm). Calibration was performed with every e periment. Samples were protected from light. Furthermore, commercially available and pre ® + sirolimus mm, nominal diameter 3.5 s Medizinische Apparate GmbH, Germany) were tested using the same setup. The contained drug substance sirolimus, also known as rapamycin, is poorly soluble in a log P value of 5.8 [1 The collected media samples were immediat ), frozen, and stored at analysis. Quantification of the sirolimus released was pe (Gerätebau Dr. Ing. Herbert , Germany) equipped with a dega r 5000), mixing chamber, pump (Smartline 1000), autosampler (Smartline 3800), column oven (Jet Steam Oven) and a UV-detector (Sma column (Eurospher 100, 120 x 4 µm) was kept at a temperature of out the separation. The chromatography was performed under isocratic conditions with a mobile phase consisting of acetonitrile/water (65/35 v/v). The flow rate mL/min. UV detection was conducted at a . The injected sample and the retention time amounted to 7.5 port of the haemostatic valve thus avoiding media loss during stent advancement. The second port was connected to a red saline pH 7.4 heated °C was pumped through the system (haemostatic valve, guiding catheter and tube) at a flow rate of mL/min which corresponds to the blood flow velocity ]. The mounted stent was rapidly adthe perfused model until reaching the rest-1). The time required to 30 s. The stent was retained in this position until the perfusion was termiuding the advancement through the guiding catheter). The media was collected in fractions by changing the collecting container of model substance released into remaining in the stent ermined after stent retrieval and subseThe model was evaluated using stents coated with two model fluorescent substances of differing solubility propcoated with triamterene ], log P 1.25 [9] ) or fluo-10], log P -1.52 ]) embedded in a polymethacrylate blend (Eudragit RL/RS ratio 3/7). Released model substance content was samples of 200 µl each well plate and fluorescence intensity was measured using a fluorescence reader (Varioskan Thermo Fisher Scientific Inc., USA; triamterene nm; fluorescein sodium λ ex 490 nm, nm). Calibration was performed with every experiment. Samples were protected from light. Furthermore, commercially available and pre-mounted irolimus-eluting coromm, nominal diameter 3.5 mm, s Medizinische Apparate GmbH, Germany) were tested using the same setup. The contained drug substance sirolimus, also known as rapamycin, is poorly soluble in a log P value of 5.8 [13] . The collected media samples were immediately diluted ), frozen, and stored at -80°C until analysis. Quantification of the sirolimus released was perGerätebau Dr. Ing. Herbert , Germany) equipped with a degasr 5000), mixing chamber, pump (Smartline 1000), autosampler (Smartline 3800), detector (Smarcolumn (Eurospher 100, 120 x 4 µm) was kept at a temperature of out the separation. The chromatography was performed under isocratic conditions with a mobile phase . The flow rate mL/min. UV detection was conducted at a . The injected sample volume was and the retention time amounted to 7.5 min. ring stent advancement. The second port was connected to a red saline pH 7.4 heated °C was pumped through the system (haemostatic valve, guiding catheter and tube) at a flow rate of mL/min which corresponds to the blood flow velocity dt-1). The time required to 30 s. The stent iellected in fractions by changing the collecting container of model substance released into remaining in the stent e-
The model was evaluated using stents coated with two pcoated with triamterene o-1.52 ]) embedded in a polymethacrylate blend (Eudragit RL/RS ratio 3/7). Released model substance content was µl each n-(Varioskan triamterene nm, xmounted omm, s Medizinische Apparate GmbH, Germany) were tested using the same setup. The contained drug substance sirolimus, also known as rapamycin, is poorly soluble in ely diluted 80°C until rGerätebau Dr. Ing. Herbert sr 5000), mixing chamber, pump (Smartline 1000), autosampler (Smartline 3800), rcolumn (Eurospher 100, 120 x 4 µm) was kept at a temperature of out the separation. The chromatography was performed under isocratic conditions with a mobile phase . The flow rate mL/min. UV detection was conducted at a volume was
The amount remaining in the stent coatings ing period as well as two untreated reference stents determined with the same method after fourfold elution of the retrieved stents tion of the samples with water (1 + 1
Results
The results of the drug loss studies during the advancement to the simulated site of implantation for fluorescein sodium and triamtere The cumulated amounts released are age of the sum of the model substance detected in the m dia fractions and in the stent coating.
Figure 2 Cumulative fluorescein sodium into media over time
Hydrophilic fluorescein sodium was released rapidly from the stent coating which result the advancement through the artery model. After only 30 54 % of the model substance had been media. After this time the stent had barely reached the res ing position and it seems unlikely that the site of implant tion could be reached much faster, especially since in vivo the right positioning has to be verified prior to expansi At the end of the experiment a of the fluorescein sodium had been released into the flo ing media and would not be available at the stenosed ve sel portion if this was indeed an implantation in vivo.
Figure 3 Cumulative t media over time
The amount remaining in the stent coatings ing period as well as two untreated reference stents determined with the same method after fourfold elution of the retrieved stents in 4 mL methanol and subsequent dil tion of the samples with water (1 + 1
Results
The results of the drug loss studies during the advancement to the simulated site of implantation for fluorescein sodium ene coated stents are given in figure The cumulated amounts released are age of the sum of the model substance detected in the m dia fractions and in the stent coating.
Cumulative fluorescein sodium into media over time, n = 6, means Hydrophilic fluorescein sodium was released rapidly from the stent coating which result the advancement through the artery model. After only 30 % of the model substance had been media. After this time the stent had barely reached the res ing position and it seems unlikely that the site of implant tion could be reached much faster, especially since in vivo the right positioning has to be verified prior to expansi the end of the experiment a of the fluorescein sodium had been released into the flo ing media and would not be available at the stenosed ve sel portion if this was indeed an implantation in vivo.
Cumulative triamterene fraction released into media over time, n = 6, means
The amount remaining in the stent coatings ing period as well as two untreated reference stents determined with the same method after fourfold elution of mL methanol and subsequent dil tion of the samples with water (1 + 1 v/v
The results of the drug loss studies during the advancement to the simulated site of implantation for fluorescein sodium coated stents are given in figure The cumulated amounts released are presented age of the sum of the model substance detected in the m dia fractions and in the stent coating.
Cumulative fluorescein sodium , n = 6, means ± SD.
Hydrophilic fluorescein sodium was released rapidly from the stent coating which resulted in vast initial losses during the advancement through the artery model. After only 30 % of the model substance had been media. After this time the stent had barely reached the res ing position and it seems unlikely that the site of implant tion could be reached much faster, especially since in vivo the right positioning has to be verified prior to expansi the end of the experiment after 5 min perfusion, 82 of the fluorescein sodium had been released into the flo ing media and would not be available at the stenosed ve sel portion if this was indeed an implantation in vivo.
riamterene fraction released into , n = 6, means ± SD.
The amount remaining in the stent coatings after the tes ing period as well as two untreated reference stents determined with the same method after fourfold elution of mL methanol and subsequent dil v).
The results of the drug loss studies during the advancement to the simulated site of implantation for fluorescein sodium coated stents are given in figure 2 and 3 . presented in percen age of the sum of the model substance detected in the m Cumulative fluorescein sodium fraction released SD.
Hydrophilic fluorescein sodium was released rapidly from in vast initial losses during the advancement through the artery model. After only 30 % of the model substance had been released into the media. After this time the stent had barely reached the res ing position and it seems unlikely that the site of implant tion could be reached much faster, especially since in vivo the right positioning has to be verified prior to expansi min perfusion, 82 of the fluorescein sodium had been released into the flo ing media and would not be available at the stenosed ve sel portion if this was indeed an implantation in vivo.
riamterene fraction released into after the testing period as well as two untreated reference stents was determined with the same method after fourfold elution of mL methanol and subsequent dilu-
The results of the drug loss studies during the advancement to the simulated site of implantation for fluorescein sodium 2 and 3. in percentage of the sum of the model substance detected in the mefraction released Hydrophilic fluorescein sodium was released rapidly from in vast initial losses during the advancement through the artery model. After only 30 s released into the media. After this time the stent had barely reached the resting position and it seems unlikely that the site of implantation could be reached much faster, especially since in vivo the right positioning has to be verified prior to expansion. min perfusion, 82 % of the fluorescein sodium had been released into the flowing media and would not be available at the stenosed vessel portion if this was indeed an implantation in vivo.
riamterene fraction released into The hydrophobic model substance triamterene was r leased much slower from the polymethacrylate coating. During the perfusion in the artery model triamterene was released steadily resul dissolution in the media of 1 the complete 5 the artery model, an overall drug loss of In the case of the tested Cypher amount released into the media was below the limit of quantification Stent consists of the drug containing layer, in which s rolimus is dissolved or suspended in a 50/50 mixture of the polymers meth [14] . Therefore, the drug has to pass this topcoat prior to its release from the coating. This seems to be the reason why no sirolimus was released into the med of the determination of the drug load remaining in the coating 5 min The residual sirolimus load of the test stents ranged from 171 µg to 194 coating of the 18 product description these detected amounts of sirolimus equal sirolimus was completed with the described fourfold elution. In the first elution st sirolimus were detected and no further release was d tected in the third and fourth elution. ceivable, that undetected drug loss might have occurred due to leased from the polymer at the time of sampling that this was not the case in our studies, two untreated reference stents was determined ( The drug load detected in these coatings was sligh with 15 during the simulated implantation procedure
The hydrophobic model substance triamterene was r leased much slower from the polymethacrylate coating. During the perfusion in the artery model triamterene was released steadily resul dissolution in the media of 1 the complete 5 min of contact with the perfusion media in the artery model, an overall drug loss of In the case of the tested Cypher amount released into the media was below the limit of quantification of 0.005 Stent consists of the drug containing layer, in which s rolimus is dissolved or suspended in a 50/50 mixture of the polymers polyethylene ethacrylate (PBMA) and a drug ]. Therefore, the drug has to pass this topcoat prior to its release from the coating. This seems to be the reason why no sirolimus was released into the med of the determination of the drug load remaining in the ing of the three test stents min are given in figure   Figure 4 Amount of stents after 5 min perfusion in the columns) and for umns).
The residual sirolimus load of the test stents ranged from µg to 194 µg. As the nominal sirolimus content of the coating of the 18 product description these detected amounts of sirolimus equal sirolimus load of the stent was completed with the described fourfold elution. In the first elution step more than 99.5 % of the overall eluted sirolimus were detected and no further release was d tected in the third and fourth elution. ceivable, that undetected drug loss might have occurred due to coating abrasion if the chipped drug wa leased from the polymer at the time of sampling that this was not the case in our studies, two untreated reference stents was determined ( The drug load detected in these coatings was sligh with 150 µg and 160 during the simulated implantation procedure
The hydrophobic model substance triamterene was r leased much slower from the polymethacrylate coating. During the perfusion in the artery model triamterene was released steadily resulting in a model substance loss due to dissolution in the media of 1 % in the first minute. After min of contact with the perfusion media in the artery model, an overall drug loss of In the case of the tested Cypher amount released into the media was below the limit of 0.005 µg/mL. Stent consists of the drug containing layer, in which s rolimus is dissolved or suspended in a 50/50 mixture of the thylenevinylacetate (PBMA) and a drug ]. Therefore, the drug has to pass this topcoat prior to its release from the coating. This seems to be the reason why no sirolimus was released into the med of the determination of the drug load remaining in the of the three test stents given in figure 4 .
Amount of sirolimus min perfusion in the for two untreated reference stents
The residual sirolimus load of the test stents ranged from µg. As the nominal sirolimus content of the coating of the 18 x 3.5 mm stent is not provid product description, the question may be raised these detected amounts of sirolimus equal load of the stent. The elution of the stent coatings was completed with the described fourfold elution. In the ep more than 99.5 % of the overall eluted sirolimus were detected and no further release was d tected in the third and fourth elution. ceivable, that undetected drug loss might have occurred coating abrasion if the chipped drug wa leased from the polymer at the time of sampling that this was not the case in our studies, two untreated reference stents was determined ( The drug load detected in these coatings was sligh and 160 µg, respectively during the simulated implantation procedure The hydrophobic model substance triamterene was r leased much slower from the polymethacrylate coating. During the perfusion in the artery model triamterene was ting in a model substance loss due to % in the first minute. After min of contact with the perfusion media in the artery model, an overall drug loss of 5 % was observed.
In the case of the tested Cypher Select ® amount released into the media was below the limit of . The coating of the Cypher Stent consists of the drug containing layer, in which s rolimus is dissolved or suspended in a 50/50 mixture of the acetate (PEVA) and (PBMA) and a drug-free polymer topcoat ]. Therefore, the drug has to pass this topcoat prior to its release from the coating. This seems to be the reason why no sirolimus was released into the med of the determination of the drug load remaining in the of the three test stents after the testing period of sirolimus determined for three min perfusion in the in vitro test model two untreated reference stents
The residual sirolimus load of the test stents ranged from µg. As the nominal sirolimus content of the mm stent is not provid the question may be raised these detected amounts of sirolimus equal
The elution of the stent coatings was completed with the described fourfold elution. In the ep more than 99.5 % of the overall eluted sirolimus were detected and no further release was d tected in the third and fourth elution. It is, however, co ceivable, that undetected drug loss might have occurred coating abrasion if the chipped drug wa leased from the polymer at the time of sampling that this was not the case in our studies, the drug load of two untreated reference stents was determined ( The drug load detected in these coatings was sligh µg, respectively. This indicates that during the simulated implantation procedure The hydrophobic model substance triamterene was released much slower from the polymethacrylate coating. During the perfusion in the artery model triamterene was ting in a model substance loss due to % in the first minute. After min of contact with the perfusion media in % was observed. ® + stents the amount released into the media was below the limit of
The coating of the Cypher ® Stent consists of the drug containing layer, in which sirolimus is dissolved or suspended in a 50/50 mixture of the (PEVA) and polybutyl free polymer topcoat ]. Therefore, the drug has to pass this topcoat prior to its release from the coating. This seems to be the reason why no sirolimus was released into the media. The results of the determination of the drug load remaining in the after the testing period of determined for three test in vitro test model (light two untreated reference stents (dark colThe residual sirolimus load of the test stents ranged from µg. As the nominal sirolimus content of the mm stent is not provided in the the question may be raised whether these detected amounts of sirolimus equal the actual The elution of the stent coatings was completed with the described fourfold elution. In the ep more than 99.5 % of the overall eluted sirolimus were detected and no further release was deIt is, however, conceivable, that undetected drug loss might have occurred coating abrasion if the chipped drug was not released from the polymer at the time of sampling. To verify the drug load of two untreated reference stents was determined (figure 4). The drug load detected in these coatings was slightly lower . This indicates that during the simulated implantation procedure indeed no loss eleased much slower from the polymethacrylate coating. During the perfusion in the artery model triamterene was ting in a model substance loss due to % in the first minute. After min of contact with the perfusion media in % was observed. stents the amount released into the media was below the limit of ® irolimus is dissolved or suspended in a 50/50 mixture of the polybutylfree polymer topcoat ]. Therefore, the drug has to pass this topcoat prior to its release from the coating. This seems to be the reason
The results of the determination of the drug load remaining in the after the testing period of test (light l-
The residual sirolimus load of the test stents ranged from µg. As the nominal sirolimus content of the ed in the whether the actual The elution of the stent coatings was completed with the described fourfold elution. In the ep more than 99. 
Conclusion
An in vitro test system to estimate drug loss during the implantation procedure of drug-eluting stents was successfully established. The model is suitable to simulate drug losses due to washout as well as losses caused by abrasive forces acting on the stent coating during the passage to the simulated site of implantation. It must be expected, however, that the situation in vivo may be even harsher when the mounted device has to pass calcified lesions. Also, elution from the coating may be influenced by the media composition. In vivo the stent coating is expected to be in contact with the blood but also with saline and contrast agents which are administered via the same port. First results using fluorescent model substances indicate that vast losses have to be expected when using fast releasing delivery systems. Therefore, the model may also prove valuable for the in vitro testing of drug-eluting balloons, which are intended to release their drug load during short contact times of approximately 60 s. Further adaptations of the experimental setup including the more realistic simulation of the arterial wall properties and the use of biorelevant media may be suitable to further improve the predictability of in vivo performance.
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